Nifty
Sensex
:
:
25476.10
83536.08
-46.40 (-0.18%)
-176.43 (-0.21%)

Pharmaceuticals & Drugs - API

Rating :
61/99

BSE: 524558 | NSE: NEULANDLAB

11968.00
09-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  11706
  •  12480
  •  11700
  •  11706.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  161166
  •  1956861276
  •  18100
  •  7753.2

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 15,358.85
  • 59.05
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 15,236.04
  • 0.10%
  • 10.08

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.68%
  • 5.45%
  • 25.86%
  • FII
  • DII
  • Others
  • 22.12%
  • 8.79%
  • 5.10%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.22
  • 9.53
  • 7.43

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.92
  • 17.10
  • 3.53

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.27
  • 26.40
  • 16.73

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.55
  • 29.08
  • 27.01

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.03
  • 4.97
  • 6.66

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.43
  • 19.27
  • 22.68

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
233.89
201.63
297.48
411.3
P/E Ratio
51.17
59.36
40.23
29.10
Revenue
1516
1477
1951
2412
EBITDA
463
323
579
780
Net Income
300
260
383
529
ROA
17.6
13
P/B Ratio
12.03
10.13
8.26
6.55
ROE
26.36
18.53
20.72
23.37
FCFF
112
113
232
331
FCFF Yield
0.8
0.81
1.66
2.37
Net Debt
-21
-228
BVPS
994.97
1181.97
1449.64
1827.66

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
328.36
385.01
-14.71%
398.03
392.83
1.32%
310.84
417.75
-25.59%
439.60
362.99
21.11%
Expenses
277.29
278.09
-0.29%
311.43
271.56
14.68%
248.62
280.26
-11.29%
316.24
266.07
18.86%
EBITDA
51.07
106.92
-52.24%
86.60
121.27
-28.59%
62.23
137.49
-54.74%
123.36
96.92
27.28%
EBIDTM
15.55%
27.77%
21.76%
30.87%
20.02%
32.91%
28.06%
26.70%
Other Income
7.46
5.36
39.18%
3.91
2.10
86.19%
4.33
3.05
41.97%
4.81
2.04
135.78%
Interest
2.35
3.61
-34.90%
2.22
3.74
-40.64%
1.06
4.43
-76.07%
2.67
2.21
20.81%
Depreciation
16.89
16.46
2.61%
16.30
15.14
7.66%
16.07
14.51
10.75%
16.28
13.59
19.79%
PBT
39.30
92.20
-57.38%
127.77
104.48
22.29%
49.42
121.59
-59.36%
129.84
83.16
56.13%
Tax
11.49
24.64
-53.37%
26.18
23.09
13.38%
16.58
32.35
-48.75%
31.97
21.28
50.23%
PAT
27.80
67.56
-58.85%
101.59
81.39
24.82%
32.84
89.25
-63.20%
97.87
61.88
58.16%
PATM
8.47%
17.55%
25.52%
20.72%
10.57%
21.36%
22.26%
17.05%
EPS
21.55
52.37
-58.85%
78.75
63.09
24.82%
25.46
69.18
-63.20%
75.86
47.96
58.17%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
-
1,476.84
1,558.58
1,191.20
951.08
936.91
762.71
666.83
527.41
578.89
509.97
Net Sales Growth
-
-5.24%
30.84%
25.25%
1.51%
22.84%
14.38%
26.43%
-8.89%
13.51%
 
Cost Of Goods Sold
-
587.64
577.29
478.23
422.14
438.42
380.20
366.24
238.37
262.90
253.46
Gross Profit
-
889.20
981.30
712.97
528.94
498.50
382.51
300.59
289.04
315.99
256.52
GP Margin
-
60.21%
62.96%
59.85%
55.61%
53.21%
50.15%
45.08%
54.80%
54.59%
50.30%
Total Expenditure
-
1,153.58
1,095.99
919.36
808.46
790.09
660.82
608.46
476.98
472.55
429.52
Power & Fuel Cost
-
50.56
48.72
48.62
42.21
39.21
32.75
26.81
25.95
25.78
22.24
% Of Sales
-
3.42%
3.13%
4.08%
4.44%
4.19%
4.29%
4.02%
4.92%
4.45%
4.36%
Employee Cost
-
272.00
257.06
201.79
182.47
149.74
123.56
110.46
102.99
92.74
65.38
% Of Sales
-
18.42%
16.49%
16.94%
19.19%
15.98%
16.20%
16.56%
19.53%
16.02%
12.82%
Manufacturing Exp.
-
112.31
107.79
86.94
89.16
77.10
64.84
50.10
55.54
44.90
39.31
% Of Sales
-
7.60%
6.92%
7.30%
9.37%
8.23%
8.50%
7.51%
10.53%
7.76%
7.71%
General & Admin Exp.
-
67.29
60.91
51.22
35.80
38.93
27.75
27.49
33.32
28.30
29.72
% Of Sales
-
4.56%
3.91%
4.30%
3.76%
4.16%
3.64%
4.12%
6.32%
4.89%
5.83%
Selling & Distn. Exp.
-
41.35
33.94
29.58
27.40
34.63
18.30
18.28
14.04
11.16
17.52
% Of Sales
-
2.80%
2.18%
2.48%
2.88%
3.70%
2.40%
2.74%
2.66%
1.93%
3.44%
Miscellaneous Exp.
-
22.42
10.29
22.99
9.28
12.08
13.42
9.08
6.77
6.78
17.52
% Of Sales
-
1.52%
0.66%
1.93%
0.98%
1.29%
1.76%
1.36%
1.28%
1.17%
0.37%
EBITDA
-
323.26
462.59
271.84
142.62
146.82
101.89
58.37
50.43
106.34
80.45
EBITDA Margin
-
21.89%
29.68%
22.82%
15.00%
15.67%
13.36%
8.75%
9.56%
18.37%
15.78%
Other Income
-
20.51
12.54
9.75
2.08
16.10
3.89
3.49
4.53
1.17
1.78
Interest
-
8.30
14.00
13.07
13.50
17.90
21.57
15.66
18.93
21.09
24.48
Depreciation
-
65.55
59.70
52.78
49.04
39.68
31.28
25.86
22.10
19.23
15.74
PBT
-
269.93
401.44
215.75
82.16
105.33
52.92
20.34
13.93
67.19
42.00
Tax
-
86.22
101.36
52.23
18.34
24.70
36.71
3.90
1.87
20.32
14.92
Tax Rate
-
24.90%
25.25%
24.21%
22.32%
23.45%
69.37%
19.17%
13.42%
30.24%
35.52%
PAT
-
260.11
300.08
163.52
63.82
80.63
16.21
16.44
12.06
46.86
27.33
PAT before Minority Interest
-
260.11
300.08
163.52
63.82
80.63
16.21
16.44
12.06
46.86
27.08
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.25
PAT Margin
-
17.61%
19.25%
13.73%
6.71%
8.61%
2.13%
2.47%
2.29%
8.09%
5.36%
PAT Growth
-
-13.32%
83.51%
156.22%
-20.85%
397.41%
-1.40%
36.32%
-74.26%
71.46%
 
EPS
-
203.21
234.44
127.75
49.86
62.99
12.66
12.84
9.42
36.61
21.35

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
1,524.81
1,282.70
994.10
840.50
786.46
709.96
699.31
558.04
545.62
186.63
Share Capital
12.90
12.90
12.90
12.90
12.90
12.90
12.90
8.95
8.95
8.95
Total Reserves
1,511.91
1,269.80
981.20
827.60
773.56
697.06
686.41
238.24
225.81
177.68
Non-Current Liabilities
189.39
122.17
146.71
179.83
169.82
163.39
104.06
146.43
54.37
69.42
Secured Loans
90.73
44.92
74.25
104.25
88.13
77.37
60.72
103.49
29.81
33.40
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
12.00
Long Term Provisions
7.22
7.61
10.29
11.91
9.44
12.49
11.91
9.87
9.28
6.85
Current Liabilities
465.69
427.68
438.96
363.16
368.51
357.63
326.98
366.93
285.60
268.00
Trade Payables
252.20
191.96
171.01
117.38
152.13
115.56
119.68
124.29
85.92
83.86
Other Current Liabilities
211.30
234.01
244.87
152.35
158.75
71.63
57.45
41.83
47.18
55.02
Short Term Borrowings
0.00
0.00
11.16
92.21
56.98
168.17
149.06
199.20
151.08
123.63
Short Term Provisions
2.19
1.72
11.93
1.21
0.64
2.27
0.80
1.59
1.41
5.50
Total Liabilities
2,179.89
1,832.55
1,579.77
1,383.49
1,324.79
1,230.98
1,130.35
1,071.40
885.59
524.05
Net Block
954.92
804.64
738.19
747.70
696.94
622.76
511.69
445.01
435.74
138.77
Gross Block
1,238.23
1,069.76
950.36
913.27
826.48
714.33
575.44
483.45
454.74
291.78
Accumulated Depreciation
283.31
265.12
212.17
165.57
129.54
91.57
63.75
38.44
19.00
153.00
Non Current Assets
1,040.38
911.48
818.87
802.70
775.20
715.79
676.88
624.20
510.54
209.87
Capital Work in Progress
47.66
45.89
40.57
20.46
17.25
23.75
104.47
126.09
19.60
40.48
Non Current Investment
1.53
1.28
0.52
0.50
19.35
30.17
30.21
30.21
30.20
7.39
Long Term Loans & Adv.
36.04
40.47
20.24
14.38
41.67
35.81
30.51
22.66
24.79
22.73
Other Non Current Assets
0.23
0.17
0.00
0.00
0.00
3.30
0.00
0.22
0.22
0.50
Current Assets
1,139.50
921.08
760.89
580.79
549.59
515.19
453.47
447.19
375.04
314.19
Current Investments
107.68
0.00
0.00
3.38
6.46
7.50
7.50
7.50
7.50
0.00
Inventories
385.76
350.42
279.23
265.21
247.61
219.55
192.65
175.09
135.11
126.66
Sundry Debtors
315.72
373.53
361.77
234.33
217.73
189.89
164.02
193.92
181.11
119.11
Cash & Bank
258.82
116.80
59.10
20.36
19.40
46.98
37.84
17.26
12.49
9.71
Other Current Assets
71.52
18.30
13.70
11.52
58.39
51.27
51.46
53.43
38.83
58.70
Short Term Loans & Adv.
51.82
62.03
47.09
46.00
49.55
33.80
31.77
37.15
25.30
46.68
Net Current Assets
673.81
493.40
321.94
217.64
181.08
157.55
126.49
80.27
89.45
46.18
Total Assets
2,179.88
1,832.56
1,579.76
1,383.49
1,324.79
1,230.98
1,130.35
1,071.39
885.58
524.06

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
317.38
261.18
237.21
60.39
189.36
57.34
69.91
11.27
38.68
44.83
PBT
346.33
401.44
215.75
82.16
105.33
52.92
20.34
13.93
67.19
42.00
Adjustment
-12.00
62.08
77.93
66.30
40.08
58.28
39.11
40.43
43.96
33.73
Changes in Working Capital
57.78
-90.73
-12.83
-67.58
49.22
-49.17
15.47
-40.02
-55.94
-19.17
Cash after chg. in Working capital
392.11
372.78
280.84
80.88
194.63
62.03
74.91
14.35
55.20
56.56
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-74.73
-111.60
-43.63
-20.49
-5.27
-4.68
-5.01
-3.08
-16.52
-11.73
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-298.16
-149.69
-61.50
-95.52
-84.42
-48.68
-77.23
-116.29
-42.11
-19.86
Net Fixed Assets
-170.21
-121.81
-60.11
-90.00
-105.64
-58.17
-70.35
-135.20
-142.08
-27.14
Net Investments
-107.93
-0.76
3.36
21.92
11.87
0.04
0.00
-0.01
-30.31
0.12
Others
-20.02
-27.12
-4.75
-27.44
9.35
9.45
-6.88
18.92
130.28
7.16
Cash from Financing Activity
24.96
-69.28
-135.80
37.72
-113.66
-5.48
11.98
104.85
-0.09
-23.62
Net Cash Inflow / Outflow
44.19
42.21
39.92
2.59
-8.72
3.18
4.66
-0.17
-3.51
1.35
Opening Cash & Equivalents
87.58
45.42
5.09
2.44
11.20
7.94
3.29
3.44
6.97
0.81
Closing Cash & Equivalent
131.93
87.58
45.42
5.09
2.44
11.20
7.94
3.29
3.44
2.16

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
1187.77
999.07
774.12
654.40
612.28
552.65
544.35
277.21
263.23
209.07
ROA
12.97%
17.59%
11.04%
4.71%
6.31%
1.37%
1.49%
1.23%
6.65%
5.23%
ROE
18.54%
26.38%
17.84%
7.85%
10.79%
2.30%
3.48%
5.02%
22.34%
15.64%
ROCE
23.45%
33.51%
20.94%
9.44%
12.81%
7.85%
3.99%
4.07%
15.98%
18.57%
Fixed Asset Turnover
1.28
1.54
1.28
1.09
1.22
1.18
1.26
1.13
1.57
1.86
Receivable days
85.17
86.10
91.33
86.74
79.40
84.68
97.96
129.34
93.22
87.45
Inventory Days
90.97
73.73
83.41
98.40
91.00
98.63
100.64
106.98
81.29
84.66
Payable days
137.94
114.75
110.05
116.52
111.44
65.43
75.72
82.06
67.03
85.01
Cash Conversion Cycle
38.21
45.08
64.68
68.63
58.96
117.88
122.89
154.27
107.48
87.10
Total Debt/Equity
0.09
0.06
0.12
0.28
0.22
0.37
0.33
1.30
0.82
0.98
Interest Cover
42.74
29.68
17.51
7.09
6.89
3.45
2.30
1.74
4.19
2.72

News Update:


  • USFDA inspects Neuland Laboratories’ Unit 2 manufacturing facility in Telangana
    3rd May 2025, 16:22 PM

    The FDA issued Form 483, with one observation related to building and facility management

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.